Clear All
777 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
NA Axitinib Axitinib 1 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR Yes 2012 In Use
NA Zanubrutinib Brukinsa 80mg Chemotherapy Tyrosine Kinase Inhibitor BTK Yes 2019 In Use
NA Cervarix Human papillomavirus vaccine 20 mcg vaccine Ancillary Therapy Protective Agent HPV Vaccine No 2009 2016 In Use
NA idelalisib Zydelig 150 mg Chemotherapy Enzyme Inhibitor PI3K Yes 2014 In Use
NA Trametinib Mekinist 2 mg Chemotherapy MEK Inhibitor BRAF Yes 2013 In Use
N/A Calcium folinate Lederle Leucovorin 5mg Ancillary Therapy Chemoprotective Antidote Yes 2025 In Use
Not yet assigned Tisagenlecleucel Kymriah consult labeling Immunotherapy CAR-T CD19 No 2017 In Use
NA Chlorotrianisene Anisene 12 mg Hormonal Therapy Estrogen Yes 1992 1997 In Use
NA Carmustine wafer Gliadel 7.7mg Chemotherapy Alkylating Agent Nitrosourea No 2012 In Use
NA Nilutamide Anadron, Nilandron 150 mg Hormonal Therapy Androgen Receptor Inhibitor Yes 1996 In Use
NA ixazomib Ninlaro 2.3 mg Chemotherapy Proteasome Inhibitor 20S Yes 2015 In Use
NA Umbralisib Ukoniq 260.2mg Chemotherapy Enzyme Inhibitor PI3Kδ, CK1ε, ABL1, CXCL12, CCL19 Yes 2021 In Use
Inavolisib Itovebi 3mg, 9mg Chemotherapy Enzyme Inhibitor PI3K⍺ Yes 2024 In Use
NA Larotrectinib Vitrakvi 25mg, 100mg 20mg/ml Chemotherapy Tyrosine Kinase Inhibitor TRK Yes 2018 In Use
NA Alpelisib Piqray 150mg Chemotherapy Enzyme Inhibitor PI3K Yes 2019 In Use
NA Estrogens, Conjugated Cenestin, Duavee, Enjuvia, Premarin, Premphase, Prempro Cenestin®, Duavee® (combination), Enjuvia®, Premarin®, Premarin® Intravenous, Premphase® (combination), Prempro® (combination) multiple Hormonal Therapy Estrogen Yes 1998 In Use
Asciminib Scemblix 20mg,40mg Chemotherapy Tyrosine Kinase Inhibitor ABL/BCR-ABL1 Yes 2021 In Use
NA Imatinib mesylate Gleevec 400 mg Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Yes 2001 In Use
NA Bexarotene Targretin 75mg Chemotherapy Immunomodulator Retinoic Acid Derivative Yes 2014 In Use
NA Nilotinib Tasigna 200 mg Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Yes 2007 In Use
Vimseltinib Romvimza 14mg, 20mg, 30mg Chemotherapy Tyrosine Kinase Inhibitor CSF1R Yes 2025 In Use
Not yet assigned Inotuzumab Ozogamicin Besponsa 0.9 mg Immunotherapy Drug Antibody Conjugate CD22 No 2017 In Use
N/A SEVABERTINIB Hyrnuo 10mg Chemotherapy Tyrosine Kinase Inhibitor HER2, EGFR Yes 2025 In Use
NA Thalidomide Thalomid 150 mg Immunotherapy Immunomodulator Thalidomide Analog Yes 1998 In Use
NA Anagrelide Agrylin 1mg Ancillary Therapy Platelet-Reducing Agent PDE-3 Inhibitor Yes 1997 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.